Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Revenues, Losses Down in Last Quarter Prior to Merger with Genesoft

NEW YORK, March 5 (GenomeWeb News) - Genome Therapeutics reported decreased revenues and losses for the fourth quarter of 2003 today, the last quarter prior to its merger with Genesoft Pharmaceuticals, which was completed last month.


The company recorded $1.7 million in revenues, down from $5.8 million during the same period last year.


R&D expenses reached $4.6 million, down from $7.1 million year-over-year.


Genome Therapeutics reported a net loss of $1.3 million, or $.04 per share, down from $8.8 million, or $.38 per share, during the year-ago period.


As of Dec. 31, the company had $29 million in cash, cash equivalents, and marketable securities. This does not include $81 million in net proceeds Genome Therapeutics raised last month in conjunction with its merger with Genesoft.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.